Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
PFA technology is only marketed in Europe, and yet, it has been dominating the electrophysiology market by storm
Tagrisso is projected to be a pivotal contributor to AstraZeneca’s portfolio
Lokavant provides clinical trial intelligence
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Biosergen AB is developing BSG005 for the treatment of severe and difficult-to-treat invasive fungal diseases
Appointment further strengthens company’s expertise in fastest-growing therapeutic area to meet patient need
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
Subscribe To Our Newsletter & Stay Updated
